<p class="typography-body-regular">Momentum continues to build for New Drug Discovery with our MDMA-like medicine programs!</p>

<p class="typography-body-regular"><br></p>

<p class="typography-body-regular">The number of MDMA-analogue compounds developed by Emyria and partner University of Western Australia (UWA) shipped for safety screening is now over 140, with fourteen new compounds sent for analysis by Eurofins.</p>

<p class="typography-body-regular"><br></p>

<p class="typography-body-regular">We have been working with the UWA to <a class="text-primary-green-dark underline" href="https://www.afr.com/companies/healthcare-and-fitness/medical-mdma-focus-for-forrest-s-new-250m-health-tech-fund-20220815-p5b9ty"><strong>develop MDMA-like compounds</strong></a><strong> </strong>to become potential treatments for neurological and psychological disorders. Take a look at our deep dive into the potential of <a class="text-primary-green-dark underline" href="https://www.youtube.com/watch?v=suZbQ3Bxuj8&amp;t=3s"><strong>MDMA-like medicine in our latest webinar </strong></a>if you missed it. UWA Associate Professor Matt Piggott and I discuss MDMA analogues in-depth and what's on the horizon for Emyria's New Drug Discovery program. We also touch on our partnership with PsychoGenics and what therapeutic potential we can identify with our MDMA-like analogues.</p>

<p class="typography-body-regular"><br></p>

<p class="typography-body-regular">Follow along our journey at <a class="text-primary-green-dark underline" href="http://emyria.com/"><strong>emyria.com</strong></a> and here in the new interactive Investor Hub.</p>

<p class="typography-body-regular"><br></p>

<p class="typography-body-regular">We welcome you to ask direct questions and discuss all of our announcements.</p>

<p class="typography-body-regular"><br></p>

<p class="typography-body-regular">Kind regards,<br>

Michael Winlo<br>

<strong>Emyria MD, CEO</strong></p>